National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

tiacumicin B
A narrow-spectrum, 18-membered macrolide antibiotic isolated from the actinomycete Dactylosporangium aurantiacum subsp. hamdenensis with potential antibacterial activity. Although the exact mechanism of action has yet to be fully elucidated, tiacumicin B may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Tiacumicin B appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:clostomicin B1
difimicin
lipiamycin A3
Code names:OPT-80
PAR-101



Previous:Thymoglobulin, thymopentin, Thyrogen, thyroxine, Thytropar
Next:tiazofurin, tibolone, ticilimumab, Tifosyl, timonacic

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov